With the support of the Lily Foundation, University of Cambridge Neurologist Dr Jelle van den Ameele and AIBN group leader Dr Seth Cheetham are hoping to change the fortunes of those born with a fatal condition.
A new facility at the Australian Institute for Bioengineering and Nanotechnology is set to provide researchers with cancer vaccines tailored to individual patients.
A new parcel of federal funding will help AIBN researchers produce clinical-grade mRNA products that are safer and better quality, and will potentially cost less.
As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.
Current mRNA therapeutics and vaccines are designed for high and ubiquitously translation. However, for many mRNA drugs and gene therapies the expression of the therapeutic RNA in all cells is undesirable and translational control must be tailored to the target tissue.
Australian Institute for Bioengineering and Nanotechnology researchers have scored crucial funding wins as they push to create the next generation of medicines and treatments.
